Unknown

Dataset Information

0

Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.


ABSTRACT: We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset of multiple myeloma cells. In this study, our objective was to investigate the metabolic basis of resistance to ritonavir and to determine the utility of cotreatment with the mitochondrial complex I inhibitor metformin to target compensatory metabolism.We determined combination indices for ritonavir and metformin, impact on myeloma cell lines, patient samples, and myeloma xenograft growth. Additional evaluation in breast, melanoma, and ovarian cancer cell lines was also performed. Signaling connected to suppression of the prosurvival BCL-2 family member MCL-1 was evaluated in multiple myeloma cell lines and tumor lysates. Reliance on oxidative metabolism was determined by evaluation of oxygen consumption, and dependence on glutamine was assessed by estimation of viability upon metabolite withdrawal in the context of specific metabolic perturbations.Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism. Ritonavir sensitized multiple myeloma cells to metformin, effectively eliciting cytotoxicity both in vitro and in an in vivo xenograft model of multiple myeloma and in breast, ovarian, and melanoma cancer cell lines. Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo.FDA-approved ritonavir and metformin effectively target multiple myeloma cell metabolism to elicit cytotoxicity in multiple myeloma. Our studies warrant further investigation into repurposing ritonavir and metformin to target the metabolic plasticity of myeloma to more broadly target myeloma heterogeneity and prevent the reemergence of chemoresistant aggressive multiple myeloma.

SUBMITTER: Dalva-Aydemir S 

PROVIDER: S-EPMC5571862 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.

Dalva-Aydemir Sevim S   Bajpai Richa R   Martinez Maylyn M   Adekola Kehinde U A KU   Kandela Irawati I   Wei Changyong C   Singhal Seema S   Koblinski Jennifer E JE   Raje Noopur S NS   Rosen Steven T ST   Shanmugam Mala M  

Clinical cancer research : an official journal of the American Association for Cancer Research 20141226 5


<h4>Purpose</h4>We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset of multiple myeloma cells. In this study, our objective was to investigate the metabolic basis of resistance to ritonavir and to determine the utility of cotreatment with the mitochondrial complex I inhibitor metformin to target compensatory metabolism.<h4>Experimental design</h4>We determined combination indices for ritonavir and metformin, impact on myeloma cell  ...[more]

Similar Datasets

| S-EPMC7541704 | biostudies-literature
| S-EPMC6379390 | biostudies-literature
2023-11-27 | GSE196766 | GEO
| S-EPMC8014887 | biostudies-literature
| S-EPMC8092590 | biostudies-literature
| S-EPMC6476731 | biostudies-literature
| S-EPMC4959642 | biostudies-literature
2024-07-25 | PXD054126 | Pride
| S-EPMC5536290 | biostudies-other